Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
Date:7/30/2013

3, general and administrative expenses increased three percent to $9.0 million from $8.7 million for the corresponding period in 2012.

Consolidated Net Loss:  Net loss for the three months ended June 30, 2013 was $29.1 million, or $0.06 per share, compared to a net loss of $25.9 million, or $0.05 per share, in the corresponding period in 2012.  Net loss for the six months ended June 30, 2013 was $55.1 million, or $0.11 per share, compared to a net loss of $55.8 million, or $0.12 per share, for the corresponding period in 2012.  For the three and six months ended June 30, 2013, net loss included non-cash, stock-based compensation expense of $1.9 million and $4.0 million, respectively. For the three and six months ended June 30, 2012, net loss included non-cash, stock-based compensation expense of $1.6 million and $3.3 million, respectively.

Cash and Investments:  As of June 30, 2013, Lexicon had $175.4 million in cash and investments, as compared to $197.2 million as of March 31, 2013 and $223.2 million as of December 31, 2012. 

Lexicon Conference CallLexicon management will hold a conference call to discuss its clinical development progress and financial results for the second quarter of 2013 at 11:00 a.m. Eastern Time on July 30, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 22881223. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through August 30, 2013.

About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon to Report Second Quarter Financial Results on July 30, 2013
2. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
3. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
4. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
5. Lexicon To Present At The Jefferies Global Healthcare Conference
6. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
8. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
9. Lexicon to Report First Quarter Financial Results on May 10, 2013
10. Lexicon To Present At The Needham Healthcare Conference
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... BARCELONA , Spanje, July 4, 2015 ... SIR-Spheres® Y-90 harsmicrosferen aan eerstelijns chemotherapie voor ... de lever (mCRC) verlengt de progressievrije overleving ... met niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die ... grootste verbetering gezien in progressievrije overleving (PFS) ...
(Date:7/3/2015)... Mexique, July 3, 2015 ... les épidémies que sont l,hypertension, le diabète et ... de plateformes éducatives gratuites et d,une conférence majeure ... http://photos.prnewswire.com/prnh/20150630/227033 ) , Les ... ligne , Prendre en charge l,hypertension en ...
(Date:7/2/2015)... , July 3, 2015 ... adquisición del 100% de participación en ZAO "Biocom" ... adquisición marca la incursión de Lupin en el ... de RUB en ventas, colocándolo como uno de ... 2014 (IMS Health). Durante más de una década, ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3
... Direct from Positive Blood CulturesFaster Results to Help Clinicians ... and VEDBAEK, Denmark, April 28 AdvanDx today announced ... for all CE-IVD marked PNA FISH(R) tests in Europe. ... time from the original 2.5 hours to 90 minutes ...
... April 27 Men taking generic drugs may be ... adverse events than if they were using branded medications, ... Researchers presented a study at the 104th Annual Scientific ... generic substitutes for alpha blockers and 5-alpha reductase inhibitors ...
Cached Medicine Technology:AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe 2AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe 3Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms 2
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker ... at the University of Minnesota, they knew it would save the university energy ... an award-winning choice: the total energy savings after installation was an impressive 89 ...
(Date:7/2/2015)... Vancouver, BC (PRWEB) , ... July 02, 2015 , ... With summer in full swing, ... , Canada is one of the top spots for fishing in the world, and it’s ... and rivers of Ontario, Canada has great fish. , Recreational fishing is a huge ...
(Date:7/2/2015)... ... ... “ LIFX ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... the market. , According to the U.S. Department of Energy, it’s very important to ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of his 80th birthday, Don ... awareness and money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk ... Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making his ...
Breaking Medicine News(10 mins):Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... 4 (HealthDay News) -- ,Most people who live near fast-food ... may put on a few extra pounds, according to a ... that living near fast-food restaurants and other unhealthy food outlets ... the past few decades. Researchers analyzed 30 years of ...
... combination of chemotherapy and radiation significantly improved the 5-year ... (NPC), according to a phase III study published Nov. ... Cancer Institute. Nasopharyngeal carcinoma is endemic ... has been the primary treatment. Although the National Comprehensive ...
... News) -- Over-the-counter "thyroid support" supplements commonly used for ... and may pose a health threat, a new study ... two kinds of thyroid hormones -- triiodothyronine (T3) and ... animal thyroid glands, according to senior investigator Dr. Victor ...
... one occurs. While errors should be avoided as much as ... not and will never be perfect; errors and adverse events ... the study, "Nurses, Perceptions of Error Reporting and Disclosure in ... Journal of Nursing Care Quality , the authors found ...
... clinical trial of the medical food Souvenaid confirmed that ... people with mild Alzheimer,s disease (AD). Results of ... at the 4th International Conference on Clinical Trials in ... Nov. 4, 2011 by Philip Scheltens, MD, PhD, Professor ...
... News) -- Delaying treatment for a herniated disc beyond six ... A study of nearly 1,200 U.S. patients found that ... disc symptoms had less pain and disability years later than ... in the study were older than 18 years and treated ...
Cached Medicine News:Health News:Fast-Food Outlets Nearby Might Not Cause Weight Gain 2Health News:Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients 2Health News:Buyer, Beware of Over-the-Counter Thyroid Supplements: Study 2Health News:New study from NYUCN is the first to look at nursing error disclosure in nursing homes 2Health News:Nutritional intervention helps in mild Alzheimer's disease 2Health News:Timing May Be Key to Successful Back Surgery 2
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
Shoulder Subluxation Inhibitor (SSI) is an ideal bracing system to keep athletes on the field by reducing the risk of shoulder injury. The SSI is the only brace that allows TOTAL ANTERIOR RANGE OR MO...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... single size, the Sierra Universal Collar fits the ... the comfort and motion restriction needed to protect ... the right size for the right fit . ... size and compact design alleviate storage problems, the ...
Medicine Products: